Chemotherapy of testis cancer: A review
β Scribed by Stephen D. Williams; Bruce J. Roth
- Publisher
- Elsevier Science
- Year
- 1992
- Tongue
- English
- Weight
- 638 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0360-3016
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
This paper compiles and reviews the data on chemotherapy with single drugs and multiple drug combinations in gastric cancer. Of the more than two dozen individual agents that have been used, only a few have been adequately evaluated, and just three (5-fluorouracil, Mitomycin C, and BCNU) exhibit cli
Testis cancer affects 2-3 men per every 100,000 in the United States, making it the most common solid tumor of men in the 20-35-year-old age range. Since the average age of active duty military personnel is included in the age range of those at greatest risk for germ cell testis cancer, it is of per
## Abstract Despite proven benefits of neoadjuvant chemotherapy in patients with locally advanced, invasive breast cancer, no regimen is recommended as the treatment of choice. Neoadjuvant chemotherapy regimens encompass singleβagent and combination therapy and sequential treatment. For this report